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Abstract
Purpose Owing to its genetic heterogeneity and acquired resistance, triple-negative breast cancer (TNBC) is not responsive 
to single-targeted therapy, causing disproportional cancer-related death worldwide. Combined targeted therapy strategies to 
block interactive oncogenic signaling networks are being explored for effective treatment of the refractory TNBC subtype.
Methods A broad kinase inhibitor screen was applied to profile the proliferative responses of TNBC cells, revealing resist-
ance of TNBC cells to inhibition of the mammalian target of rapamycin (mTOR). A systematic drug combination screen was 
subsequently performed to identify that AEE788, an inhibitor targeting multiple receptor tyrosine kinases (RTKs) EGFR/
HER2 and VEGFR, synergizes with selective mTOR inhibitor rapamycin as well as its analogs (rapalogs) temsirolimus and 
everolimus to inhibit TNBC cell proliferation.
Results The combination treatment with AEE788 and rapalog effectively inhibits phosphorylation of mTOR and 4EBP1, 
relieves mTOR inhibition-mediated upregulation of cyclin D1, and maintains suppression of AKT and ERK signaling, 
thereby sensitizing TNBC cells to the rapalogs. siRNA validation of cheminformatics-based predicted AEE788 targets has 
further revealed the mTOR interactive RPS6K members (RPS6KA3, RPS6KA6, RPS6KB1, and RPS6KL1) as synthetic 
lethal targets for rapalog combination treatment.
Conclusions mTOR signaling is highly activated in TNBC tumors. As single rapalog treatment is insufficient to block mTOR 
signaling in rapalog-resistant TNBC cells, our results thus provide a potential multi-kinase inhibitor combinatorial strategy 
to overcome mTOR-targeted therapy resistance in TNBC cells.
Keywords Multi-kinase inhibitor · mTOR-targeted therapy · Drug resistance · Triple-negative breast cancer (TNBC) · 
Polypharmacology
Abbreviations
BL  Basal-like
CDK4  Cyclin-dependent kinase 4
CI  Combination index
EGF  Human epidermal growth factor
FC  Fold change
IC50  Half-maximal inhibitory concentration
IM  Immunomodulatory
KI  Kinase inhibitor
LAR  Luminal androgen receptor-like
MSL  Mesenchymal stem-like
mTOR  The mammalian target of rapamycin
RTK  Receptor tyrosine kinase
SRB  Sulforhodamine B
TNBC  Triple-negative breast cancer
Background
Triple-negative breast cancer (TNBC) constitutes a small 
subtype (10–20%) of breast cancer, but causes the major-
ity of breast cancer-related deaths [1, 2]. As defined by the 
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absence of ER and PR expression and HER2 overexpression, 
TNBC is not curable by hormone receptor or HER2-targeted 
therapies [3]. Furthermore, TNBC is highly heterogeneous. 
Gene expression profiling has further classified TNBC into 
six unique molecular subtypes, namely basal-like (BL1 and 
BL2), mesenchymal (M), mesenchymal stem-like (MSL), 
immunomodulatory (IM), and luminal androgen receptor-
like (LAR) subtype [4]. The TNBC molecular signatures 
have been explored for targeted therapies in clinical trials, 
including those targeting receptor tyrosine kinases (RTKs, 
e.g., EGFR, VEGFR, c-Met), PI3K/AKT, Ras/MAPK, JAK/
STAT, cell cycle regulators [5, 6]. Yet, TNBC has not ben-
efited from above mono-targeted therapies so far, due to 
intrinsic or acquired resistance [6].
The mammalian target of rapamycin (mTOR), a con-
served serine/threonine protein kinase, is a central regulator 
of cell growth and proliferation, by sensing and integrating 
multiple signals from growth factors and nutrient signals 
[7, 8]. mTOR hyperactivity is frequently observed in TNBC 
compared to other breast cancer subtypes and is often cor-
related with poor prognosis, underpinning the potential 
of mTOR-targeted therapy for TNBC treatment [9–11]. 
Although mTOR-targeted interventions, such as rapamy-
cin and its analogs (rapalogs) temsirolimus and everoli-
mus, delay progression and extend survival, patients with 
TNBC eventually develop resistance to mTOR inhibitors 
with undesired outcome [9, 12]. Evidence has shown that 
rapalog treatment could release mTOR negative feedback on 
upstream kinases and activate compensatory pathways, for 
instance, PI3K/AKT and MAPK/ERK signaling pathways, 
thereby bypassing mTOR inhibition [13–15]. This obser-
vation underscores the need for alternative combinatorial 
therapeutic approaches for TNBC treatment.
Since oncogenic pathways incorporate multiple signaling 
components and axes to promote tumor malignancy, mono-
therapy may not be sufficient for long-term control of TNBC 
[9, 13, 16]. Hence, simultaneously targeting different sign-
aling molecules represents a promising strategy to impede 
tumor growth and progression [8, 17]. Several reports have 
documented that co-targeting growth factor receptors and 
mTOR exerts cooperative anti-cancer effects in various can-
cer types, including TNBC [18–22]. However, these studies 
focus on a particular combination in the questioned cancer 
type. Little is known about the interactive kinases involved 
in rapalog resistance and the mechanisms of the combinato-
rial effect remain unclear. Here, we systematically screened 
a broad collection of kinase inhibitors across a large panel of 
TNBC lines treated with rapamycin. Our data demonstrated 
that multiple targeted kinase inhibition, for instance, by 
inhibitor AEE788, sensitizes TNBC cells to various mTOR 
inhibitors, rapamycin, temsirolimus, and everolimus. Inte-
grated cheminformatics study and siRNA validation revealed 
additional putative targets of AEE788, which interact closely 
with mTOR signaling. Most importantly, our study provided 
an efficacious approach for exploring cancer combination 
treatment. Moreover, the combinatorial therapy is more 
effective than single drug application and thus demonstrates 
a therapeutic advantage over either agents as a monotherapy 
in TNBC treatment.
Methods
Kinase inhibitor library combination screen
One day post seeding into 96-well plates, cells were treated 
with individual kinase inhibitors alone or combined with 
rapamycin at 1 µM. After 4-day treatment, proliferation was 
evaluated by sulforhodamine B (SRB) colorimetric assay 
[23]. Detailed information on materials and methods can be 
found in Supplementary file ESM_3.
Results
TNBC cell lines are differentially responsive to mTOR 
inhibitor rapalogs
To gain insights into TNBC dependency on mTOR signaling 
integration for proliferation and cell survival, a KI library 
 (Selleckchem®) containing 378 small molecular inhibitors 
targeting various kinase signaling pathways was screened 
across 19 TNBC cell lines (Suppl. Table S1), which are 
representative for the six transcriptome-based subtypes of 
TNBC [4]. All TNBC cell lines were exposed to individual 
inhibitors at 1 µM for 4 days, followed by measurement of 
cell proliferation. The effect of each inhibitor on prolifera-
tion was assessed by Z scores normalized to overall pro-
liferative response. TNBC cell lines were largely resistant 
to the majority of the kinase inhibitors, without any clear 
correlation to the TNBC molecular subtypes (Fig. 1a). The 
proliferative response towards mTOR inhibitors was vari-
able among TNBC cell lines. We distinguished 11 TNBC 
cell lines insensitive to different mTOR inhibitors (Fig. 1b), 
including rapamycin (Rap) and its analogs (i.e., rapalogs), 
zotarolimus, everolimus, ridaforolimus, and temsirolimus. 
HCC1806 and SUM149PT were most resistant to rapologs, 
while Hs578T was most sensitive.
Rapalogs are highly selective allosteric inhibitors of 
mTOR, by binding to FKBP12/rapamycin-binding domain 
to block mTOR Ser2448 phosphorylation and function [24, 
25]. mTOR Ser2448 is a predominant phosphorylation 
residue for mTOR kinase activity in response to mitogen-
derived stimuli [25]. Therefore, we examined the inhibi-
tory effect of rapamycin (Rap), temsirolimus (Tem), and 
everolimus (Eve), on Ser2448-mTOR phosphorylation with 
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a focus on rapalog-resistant TNBC cell lines HCC1806 and 
SUM149PT and rapalog-sensitive Hs578T TNBC cells. 
The rapalogs potently inhibited phosphorylation of mTOR 
in the sensitive Hs578T cells, but not or less effectively in 
the resistant HCC1806 and SUM149PT cells, respectively 
(Fig. 1c, d). These data suggest that mTOR kinase activity 
and its sustained phosphorylation render the TNBC cells 
resistant to rapalogs.
Combinatorial drug screen identifies kinase 
inhibitors sensitizing TNBC cells to mTOR inhibition
Next, to identify kinase inhibitors synergizing with mTOR 
inhibition in rapalog refractory TNBC cells, we further 
performed a drug screen with rapamycin (at 1  µM) in 
combination with the 378 kinase inhibitors (also tested at 
1 µM) in the resistant SUM149PT cells. Pearson’s corre-
lation coefficient r displayed high reproducibility of two 
replicate screens for KI (r = 0.9509) and KI and rapamycin 
(KI + Rap, r = 0.9115), respectively (Fig. 2a, b). Compari-
son of KI + Rap combinatory effect to the single KI effect 
on proliferation inhibition uncovered 9 potent KIs (Fig. 2c), 
which significantly enhanced inhibitory effect of rapamycin 
on proliferation of SUM149PT cells (Fig.  2d). These 
included one MEK inhibitor PD184352 and 8 RTK inhibi-
tors, AEE788, afatinib, AC480, AZD8931, AZD9291, AST-
1306, ZM 306416, and gefitinib that are described to target 
single or multiple EGFR/HER2 and VEGFR RTKs (Fig. 2e). 
We also performed rapamycin combination screen in the 
resistant HCC1806 cells in parallel. As HCC1806 cells were 
responsive to EGFR inhibitors, only additive effects were 
observed (Suppl. Fig. S1c; Suppl. Fig. S2).
These data implicate that while the resistant SUM149PT 
cells poorly respond to inhibitors of EGFR or VEGFR and 
mTOR inhibitor rapamycin alone, concurrent blockage of 
upstream EGFR or VEGFR RTK activity or MEK signal-
ing transduction, and downstream mTOR signaling could 
converge re-sensitization of TNBC cells.
Multi‑targeted RTK inhibitor AEE788 enhances 
proliferative inhibition and cell death 
in rapalog‑resistant TNBC cells
Next, we further validated the combinatorial effect of the 
most promising combinations on proliferative inhibition in 
the rapalog-resistant SUM149PT cells. We focused on the 
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Fig. 1  Resistance profiling of TNBC cell lines to mTOR inhibi-
tor rapalogs. a Heatmap presenting the responses of 19 TNBC cell 
lines to 378 kinase inhibitors. Data were shown based on the effect of 
individual KI on proliferation (relative Z scores), subtype-annotated 
cell lines (clustered horizontally), and pathway-annotated inhibitors 
(clustered vertically). Strong inhibitory effect on proliferation was 
indicated in green and weak in red. b Response clustering of TNBC 
cell lines to mTOR inhibitors (mTORi). c Concentration range effects 
of rapalogs rapamycin (Rap), temsirolimus (Tem), and everolimus 
(Eve) on mTOR phosphorylation, in rapalog-resistant HCC1806 and, 
SUM149PT TNBC cells, compared to rapalog-sensitive Hs578T 
cells. Cells were treated with rapalogs in concentration range (µM) 
for 4  h. d Quantitative comparison of phosphorylated mTOR level 
to total mTOR level in rapalog-treated resistant and sensitive TNBC 
cells
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MEK inhibitor PD184352, EGFR inhibitor gefitinib, and the 
multi-targeted RTK inhibitor AEE788. Cells were treated with 
rapamycin in a concentration range alone or combined with 
different concentrations of PD184352, gefitinib, or AEE788. 
AEE788 synergized with rapamycin to inhibit SUM149PT cell 
proliferation in dose-dependent manner (Fig. 3a, top panel). 
In contrast, PD184352 and gefitinib (Suppl. Fig. S1a, b) dis-
played a more additive effect when combined with rapamycin. 
The synergistic effects of AEE788 and rapalogs, Rap, Tem, 
and Eve, were further confirmed in SUM149PT as well as 
another rapalog-resistant TNBC cell line HCC1143 (Fig. 3a). 
AEE788 significantly reduced the half-maximal inhibitory 
concentrations (IC50) of the rapalogs in both SUM149PT 
and HCC1143 cell lines (Fig. 3b). Combination index (CI) 
analysis detected the strong synergy of AEE788 and rapalogs, 
overall with CI values < 0.5 (Fig. 3c). To detect the combi-
natorial effects of AEE788 and rapamycin on TNBC cell 
death, we performed Annexin V/Propidium Iodide apoptosis 
assay in SUM149PT and HCC1143 cell lines. Besides pro-
liferative inhibition, the combination significantly enhanced 
apoptosis and necrosis 96 h post treatment in SUM149PT cells 
(Fig. 3d), and enhanced the monotherapy-induced apoptosis 
in HCC1143 cells, albeit not statistically significant (Fig. 3e). 
Next, we evaluated the combinatorial effects on normal mam-
mary cells MCF10A and renal cells RPTEC. Importantly, nei-
ther monotherapy nor combination significantly suppressed 
proliferation or induced cell death of MCF10A and RPTEC 
cells, suggesting that the combo effects might be cancer cell 
specific and less toxic in normal mammary and renal cells 
(Suppl. Fig. S3). Altogether, the KI combination not only 
inhibited TNBC cell proliferation, but also enhanced the 
monotherapy-induced apoptosis and necrosis, with minimal 
effects on normal mammary and renal cells.
KI Targets (IC50/nM)
PD184352 MEK1/2 (17)
AEE788 EGFR (2), HER2 (6), VEGFR1 (59)
Afatinib EGFR (0.5), HER4 (1)
AC480 EGFR (20), HER2 (30)
AZD8931 HER2 (3), EGFR (4)
AZD9291 EGFR (494)
AST-1306 EGFR (0.5), HER4 (0.8)
ZM 306416 VEGFR1 (330), SRC (330)
Gefitinib EGFR Tyr1173 (37)
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Fig. 3  Synergistic effect of AEE788 and rapalogs on proliferative 
inhibition and cell death in rapalog-resistant TNBC cells. a Prolif-
erative response of rapalog-resistant SUM149PT (left panel) and 
HCC1143 (right panel) TNBC cells, to rapalogs Rap, Tem, and 
Eve in concentration range alone or combined with 0.316  µM and 
1  µM AEE788, respectively. b IC50 values (µM) of rapalogs in 
combination with AEE788, inducing 50% of proliferation inhibi-
tion in SUM149PT and HCC1143 cells. c Combination index (CI) 
of rapalog and AEE788 in SUM149PT and HCC1143 cells. CI < 1 
indicates synergism. d, e Combinatorial effects of Rap and AEE788 
on SUM149PT (left panel, d) and HCC1143 (right panel, e) cell 
death. Cells were subjected to Annexin V/Propidium Iodide (AnV/
PI) apoptosis assays after treatment for 24, 48, 72, and 96 h. Cisplatin 
(100 µM) was used as positive control. (two-way ANOVA *p < 0.05, 
**p < 0.01, ***p < 0.001)
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Co‑treatment of rapamycin and AEE788 
abolishes mTOR phosphorylation and sustains 
downregulation of ERK and AKT signaling in TNBC 
cells
mTOR belongs to a complex network of regulatory feed-
back loops responsible for controlling upstream prolifera-
tive signaling pathways. The major upstream signaling in 
control of mTOR activity involves PI3K/AKT and MAPK/
ERK, the two canonical pathways downstream of RTKs [7]. 
Resistance to mTOR inhibition in cancer has been linked to 
activation of upstream PI3K/AKT and MAPK/ERK signal-
ing, following rapalog treatment [15]. Next, we investigated 
the synergistic effect of AEE788 and rapamycin on PI3K/
AKT and MAPK signaling in TNBC cells. Treatment with 
AEE788 alone inhibited ERK and AKT phosphorylation in 
the resistant SUM149PT and HCC1143 cells (Fig. 4a). Sin-
gle treatment with rapamycin slightly increased p-ERK in 
SUM149T and p-AKT in HCC1143 cells. The phosphoryla-
tion levels of mTOR and the target of mTOR, 4EBP1, were 
not affected by either AEE788 or rapamycin alone, further 
indicating the sustained mTOR signaling in the resistant 
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AEE788 and Rap co-treatment on mTOR phosphorylation, upstream 
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treated with AEE788 and Rap alone or combined as indicated. c 
Effects of AEE788 and Rap co-treatment on EGF-stimulated sign-
aling transduction in SUM149PT and HCC1143 cells. Cells were 
starved in serum-free medium overnight, pre-treated for 4  h with 
AEE788 and Rap alone or combined as indicated, followed by expo-
sure to 100 ng/ml EGF for 5 min. 4EBP1 can be phosphorylated at 
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Effects of AEE788 and Rap co-treatment on Beclin-1 accumulation. 
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ment. White arrows indicate the induction of Beclin-1
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TNBC cells. However, co-treatment of AEE788 and rapa-
mycin almost completely abolished mTOR phosphorylation, 
while ERK and AKT phosphorylation remained inhibited 
(Fig. 4a, b). The synergistic effect of AEE788 and rapamycin 
on p-4EBP1 inhibition was marginal (Fig. 4a).
As AEE788 has been described as an EGFR/VEGFR 
dual RTK inhibitor, we further evaluated the co-treatment 
effect of AEE788 and rapamycin on EGFR RTK signaling 
activity in both resistant SUM149PT and HCC1143 cells 
upon EGF stimulation (Fig. 4c). To reach maximal activa-
tion of the EGFR signaling pathway, cells were first serum 
starved followed by EGF treatment. EGF caused the activa-
tion of the EGF receptor as evidenced by increased p-EGFR 
and downstream p-ERK and p-AKT. AEE788 effectively 
blocked EGF-stimulated phosphorylation of these compo-
nents, in both SUM149PT and HCC1143 cells. It has been 
reported that 4EBP1 has multiple phosphorylation sites and 
an increase in 4EBP1 phosphorylation is accompanied by a 
decrease in its electrophoretic mobility [26–28]. EGF also 
effectively caused enhanced p-mTOR and p-4EBP1. Rapa-
mycin could inhibit 4EBP1 phosphorylation by EGF in both 
cell lines but with no (SUM149PT) or limited (HCC1143) 
effects on mTOR activation; and, reversely, AEE788 could 
inhibit mTOR activation but with marginal effects on 4EBP1 
phosphorylation. However, co-treatment with AEE788 and 
rapamycin particularly could shut down the EGF-mediated 
phosphorylation of mTOR and 4EBP1 signaling.
Several cellular processes have been linked to the immu-
nogenicity of cell death, including autophagy and ER stress 
[29–32]. Given that mTOR is a key regulator of autophagy, 
we then tested the combination effect of autophagy in TNBC 
cells. Interestingly, the combination sustained the elevated 
LC3B level induced by monotherapy and demonstrated 
accumulated Beclin-1 expression 24 h post treatment in both 
SUM149PT and HCC1143 cells (Fig. 4d, e). The combina-
tion increased the expression level of BiP, a key regulator of 
ER stress, 24 h post treatment in SUM149PT cells, but not 
so much in HCC1143 cells (Fig. 4d), suggesting the involve-
ment of immunogenic cell death-related events in TNBC 
cells by the combination treatment.
Silencing of AEE788 targets enhances mTOR 
inhibition in TNBC cells
Although AEE788 has been described as an inhibitor tar-
geting multiple RTKs, we wondered whether the effect of 
AEE788 could be related to unanticipated polypharma-
cology, thus impacting through additional mechanisms of 
mTOR signaling. We used a cheminformatics approach 
to predict candidate alternative kinase targets of AEE788. 
ChEMBL is an open large-scale bioactivity database that 
contains comprehensive target inhibition information of 
thousands of drug-like molecules, including kinase inhibitor 
activity, allowing well-informed prediction of structure-
based alternative kinase target prediction [33, 34]. We firstly 
performed ligand-based target prediction for AEE788. With 
1 µM and 10 µM activity cutoffs, 9 kinases showed high 
prediction scores and as such putative targets of AEE788, 
including RPS6KB1, AKT2, CDK7, EGFR, MAPKAPK2, 
CLK4, JAK2, AKT3, and VEGFR2 (Fig. 5a). To refine the 
scale of target list, we selected kinases showing prediction 
score greater than 0.1 and kinases with an IC50 of AEE788 
smaller than 1 µM according to the publically available data 
[35]. As a result, 30 putative kinase targets were selected. 
To validate the potential contribution of these kinases in the 
interaction with rapamycin, we performed a targeted rapa-
mycin and siRNA synthetic lethal screen in SUM149PT 
cells (Fig. 5b). The synthetic lethal screen revealed 13 can-
didate targets (Fig. 5c). We anticipated that these validated 
targets would take part in connected signaling networks and, 
therefore, would all individually impact on the rapamycin 
sensitivity. Indeed, protein–protein interaction network 
analysis revealed a close interaction of the various putative 
kinase targets of AEE788 (Fig. 5d; Suppl. Table S2). Inter-
estingly, the well-known mTOR target RPS6KB1 as well 
as other RPS6K family members RPS6KA3, RPS6KA6, 
and RPS6KL1 were mapped in the network, supporting 
the synergistic drug interaction of AEE788 with rapamy-
cin on mTOR signaling. In addition, ABL2 and PDGFRB 
were predicted and validated as potential targets involved in 
rapamycin synergy. Of relevance, rapalog-resistant TNBC 
cell lines SUM149PT, HCC1143, SUM159PT, and HCC38 
poorly responded to inhibitors targeting the verified targets 
of AEE788, including EGFR, VEGFR, PDGFR, ABL, and 
S6K (Suppl. Fig. S2). Taken together, the above data sug-
gest that AEE788 synergizes with rapamycin in suppress-
ing TNBC cell proliferation by targeting several EGFR, 
VEGFR, PDGFR, ABL, and different S6K kinases that are 
all connected to mTOR signaling.
AEE788 abolished rapalog‑upregulated cyclin D1 
expression in TNBC cells
Finally, we looked into the mechanism how AEE788 and 
rapalogs impact on cell proliferation. Inhibition of mTOR by 
rapamycin blocks cell cycle progression, and cell prolifera-
tion has been linked to disruption of the cyclin-dependent 
kinase 4 (CDK4)-cyclin D1 complex [36]. Therefore, we 
next addressed the role of cyclin D1 in the synergistic effect 
of AEE788 and rapalogs on proliferation of rapalog-resist-
ant SUM149PT and HCC1143 TNBC cell lines. Unexpect-
edly, we observed that rapalogs Rap, Tem, and Eve did not 
suppress but upregulated cyclin D1 protein expression and 
mRNA levels of CCND1 (the gene encoding cyclin D1) in 
SUM149PT and HCC1143 TNBC cells after short-term (8 h) 
and long-term (24 h) treatments (Fig. 6a–c). This suggests 
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a positive-feedback loop activation upon rapalog treatment, 
thereby counteracting the anti-proliferative effect of rapa-
logs. Rapalogs slightly increased CDK4 levels, but did not 
affect cyclin B1 expression in the TNBC cells (Fig. 6a). 
When co-treated with AEE788, the rapalog-induced cyclin 
D1 upregulation was blocked at both the mRNA and pro-
tein levels (Fig. 6a–c). Moreover, co-treatment of AEE788 
and rapalogs led to downregulation of cyclin B1 and CDK4 
expression in both TNBC cell lines (Fig. 6a). These results 
suggested that AEE788 synergized with rapalog to abro-
gate cyclin D1 upregulation thereby inhibiting cell prolifera-
tion. Next, we silenced cyclin D1 by siRNA-based CCND1 
knockdown in SUM149PT and HCC1143 cells, in combina-
tion with rapalogs Rap, Tem, and Eve, respectively. While 
silencing cyclin D1 alone considerably impaired SUM149PT 
and HCC1143 cell proliferation, this inhibitory effect was 
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significantly enhanced when combined with rapalogs Rap, 
Tem, or Eve (Fig. 6d). In support of a role of CDK4/cyclin 
D1 in the resistant phenotype of rapamycin, an enhanced 
inhibition on proliferation was observed in SUM149PT and 
HCC1143 cells when co-treated with rapamycin and selec-
tive CDK4/6 inhibitor palbociclib or LY2835219 (Suppl. 
Fig. S3), albeit not as effective as AEE788.
Discussion
mTOR acts as a central regulator of multiple signaling 
networks in control of cell growth, proliferation, and sur-
vival [7, 37]. mTOR signaling is frequently upregulated 
in malignant tumors, including TNBC, highlighting the 
potential of mTOR kinase targeted therapy in cancer 
modulation [7–9, 12]. However, patients with TNBC often 
experience mTOR targeting failure due to acquired resist-
ance and activation of bypass surviving pathways [13, 15, 
38]. Our drug combination screen revealed that co-treat-
ment with AEE788, a multiple RTK-targeted inhibitor, 
restores the sensitivity of TNBC cells towards the clini-
cally applied mTOR inhibitors (rapamycin, temsirolimus, 
and everolimus). The effect of AEE788 is likely due to 
polypharmacology to shut down the crosstalk among 
receptors as well as mTOR pathway within signaling 
networks in the resistant scenario. The combination of 
targeted agents profoundly improves therapeutic efficacy 
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and overcomes resistance that might develop under single-
agent therapy.
mTOR inhibition can relieve distinct negative feedback 
loops that normally serve to attenuate upstream RTKs, PI3K, 
and MAPK signaling, leading to rapalog resistance [39]. 
As such, mTOR inhibition alone is not sufficient to over-
come the entire oncogenic program propagated from the 
alternate proliferative signaling pathways. By exploiting a 
high-throughput kinase drug combination screen, our study 
has identified the effective kinase inhibitor, AEE788, that 
can block compensatory mechanisms conferring aberrant 
cell cycle progression upon rapalog treatment. The repres-
sion of EGFR/VEGFR- and mTOR-related pathways in con-
cert seemingly reverts processes predominantly responsible 
for uncontrolled TNBC tumor proliferation. Our results 
are in line with the above observations that co-inhibition 
of upstream RTKs (such as EGFR, VEGFR, PDGFR, and 
IGF1R), PI3K and MAPK signaling transduction, and 
mTOR signaling elicited enhanced therapeutic efficacy in 
various cancer types.
Sustained mTOR signaling drives resistance to targeted 
therapeutics in cancer treatment [38]. In TNBC tumor cells, 
mTOR signaling is frequently upregulated [40]. We demon-
strated that while rapalogs alone were insufficient to inhibit 
the sustained mTOR signaling in resistant TNBC cells, co-
treatment of rapalogs with the multi-targeted RTK inhibitor 
AEE788 synergistically blocked mTOR phosphorylation in 
SUM149PT and HCC1143 cells. Interestingly, SUM149PT 
cells have been characterized for the constitutively activated 
EGFR via a self-sustaining amphiregulin autocrine loop, and 
subsequently, altered receptor signaling and gene expression 
[41, 42]. As a further validation, AEE788 and rapamycin 
treatment blocked EGF-mediated EGFR downstream signal-
ing in both SUM149PT and HCC1143. We recognize that 
these experiments were performed under short-term EGF 
treatment conditions that may not fully reflect the normal 
TNBC cell signaling. Therefore, we cannot exclude that 
under more physiological conditions in the tumor microen-
vironment other distinct RTK signaling cascades are more 
prominent in the modulation of RTK signaling and cancer 
progression.
A mechanism of resistance to mTOR inhibition in can-
cer is the rapalog-mediated activation of upstream PI3K/
AKT and MAPK/ERK signaling [15]. Co-treatment with 
AEE788 and rapamycin maintained the inhibitory effect on 
AKT and ERK signaling in TNBC cells. These data suggest 
that AEE788 and rapamycin synergistically inhibit the sus-
tained mTOR activity in TNBC cells, thus blocking mTOR’s 
potential feedback loop on activation of alternative ERK and 
AKT proliferative signaling pathways.
Polypharmacology, the action of drugs against multiple 
targets [17], is commonly observed in drug development 
including the effective marketed kinase inhibitors [43]. Our 
ChEMBL-based cheminformatics analysis demonstrated 
that AEE788 is a kinase inhibitor that likely targets several 
kinases; this is consistent with other reports using protein 
kinase assays [19, 35]. Complementary to a recent kinobe-
ads study on target landscape of clinical kinase drugs [43], 
our cheminformatics approach presented that the multi-tar-
geted RTK inhibitor AEE788 likely interacts with EGFR, 
VEGFR, ABL2, PDGFRB, and several mTOR signaling 
pathway components, including AKT and S6K family mem-
bers. Subsequent siRNA-based knockdown of these various 
kinases, e.g., RTKs (EGFR, VEGFR2/3, and PDGFRB), 
AKTs (AKT2 and AKT3), RPS6Ks (RPS6KA3, RPS6KA6, 
RPS6KB1, and RPS6KL1), MAPKAPK2, ABL2, and 
CDK7, sensitized rapalog-resistant TNBC cells to rapa-
mycin. Several reports have demonstrated the synergistic 
effects of targeting EGFR or MEK on anti-mTOR therapies 
in TNBC [20, 44–46]. However, our study demonstrated that 
simultaneous use of EGFRi gefitinib or MEKi PD184352 
only exerts additive effects on rapamycin-mediated prolif-
erative inhibition, suggesting that AEE788-rapalog synergy 
results presumably from multi-targeted kinase inhibition. 
These data support the anticipated polypharmacology of 
AEE788 as the mode-of-action of the synergy with rapa-
logs. Further studies are required to determine the detailed 
kinome target landscape of AEE788 in TNBC.
mTOR pathway regulates cell growth through its down-
stream effectors, such as 4EBP1 and RPS6KB1 [7, 37]. 
Another primary way that mTOR confers its regulatory 
effects on cell proliferation is to upregulate expression of 
the cell cycle regulator cyclin D1 [47]. CCND1, the cyclin 
D1 encoding gene, is frequently amplified in breast cancer, 
and depletion of cyclin D1 suppresses breast cancer progres-
sion [48, 49]. In response to mTOR inhibition, however, cyc-
lin D1 is elevated by everolimus in various types of cancer 
[21, 22]. Consistently, we found that treatment with rapa-
logs (rapamycin, temsirolimus, and everolimus) commonly 
upregulated cyclin D1 in rapalog-resistant TNBC cells, indi-
cating an alternative activation of cyclin D1 proliferative 
signaling pathway after mTOR inhibition. Considering that 
cyclin D1 was lost in the presence of the AEE788-rapalog 
combination, AEE788 seems to compensate the undesired 
effects of rapalog, further highlighting the therapeutic 
advantage of the drug combination. Interestingly, while we 
discovered the AEE788-rapamycin interaction through a 
wider screening effort in TNBC cells, our findings were fur-
ther supported by the observations on the synergistic effects 
of AEE788-everolimus combination in prostate, germ, and 
renal tumor cell lines [19, 21, 22]. Moreover, a xenograft-
bearing mice study also documented the beneficial action 
of AEE788-everolimus combination in glioblastoma tumor 
regression [50]. However, these studies did not further the 
mode-of-action of AEE788. Since AEE788 is recognized 
as a multiple targeting kinase inhibitor, their observations 
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were limited to EGFR/VEGFR, lacking the notion on other 
potentially targeted candidate kinases. Our study, for the first 
time, revealed the synergy on rapalogs treatment in TNBCs 
and its underlying polypharmacology by utilizing integrated 
systematic screen and cheminformatics approach. Moreover, 
either genetic or pharmacological ablation of cyclin D1 sig-
nificantly enhanced mTOR-inhibition-mediated proliferative 
inhibition. This is concordant with the recent reports on the 
synergistic anti-cancer activity of combined CDK4/6 and 
mTOR targeting [51–53].
In conclusion, our work supports that polypharmacol-
ogy to target multiple kinase targets in combination with 
rapalog treatment may offer a distinct combinatorial benefit 
to TNBC patients that are otherwise resistant to mTOR-
targeted therapeutics.
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